Clinical Trial

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Name: A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence — clinical trial record (NCT07475026)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Neo-LENTIS

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-06

Trial Details

NCT Number	NCT07475026
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	HCC - Hepatocellular Carcinoma
Enrollment	198 participants
Start Date	2026-06-09
Primary Completion	2030-01-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-05